Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives $42.00 Consensus Target Price from Brokerages

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) have been given an average recommendation of “Moderate Buy” by the six brokerages that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, four have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $42.00.

ORKA has been the topic of several recent research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oruka Therapeutics in a research report on Saturday, September 27th. Wall Street Zen raised Oruka Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, September 20th. Wedbush reissued an “outperform” rating and issued a $40.00 price objective on shares of Oruka Therapeutics in a research report on Tuesday, August 12th. BTIG Research reissued a “buy” rating and issued a $56.00 price objective on shares of Oruka Therapeutics in a research report on Monday, September 29th. Finally, HC Wainwright reissued a “buy” rating and issued a $45.00 price objective on shares of Oruka Therapeutics in a research report on Monday, August 18th.

Oruka Therapeutics Trading Up 3.2%

Shares of NASDAQ ORKA opened at $19.79 on Friday. The stock has a market capitalization of $741.14 million, a PE ratio of -7.04 and a beta of -0.29. The stock’s fifty day simple moving average is $15.41 and its two-hundred day simple moving average is $12.64. Oruka Therapeutics has a 12-month low of $5.49 and a 12-month high of $31.13.

Oruka Therapeutics (NASDAQ:ORKA) last announced its earnings results on Monday, August 11th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.48) by $0.02. On average, equities analysts predict that Oruka Therapeutics will post -3.41 earnings per share for the current fiscal year.

Institutional Trading of Oruka Therapeutics

A number of institutional investors have recently made changes to their positions in the business. BNP Paribas Financial Markets boosted its position in shares of Oruka Therapeutics by 464.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock worth $31,000 after purchasing an additional 2,306 shares in the last quarter. Legal & General Group Plc acquired a new stake in shares of Oruka Therapeutics in the 2nd quarter worth $28,000. Ameritas Investment Partners Inc. acquired a new stake in shares of Oruka Therapeutics in the 2nd quarter worth $31,000. Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Oruka Therapeutics in the 2nd quarter worth $68,000. Finally, New York State Common Retirement Fund acquired a new stake in shares of Oruka Therapeutics in the 2nd quarter worth $96,000. Institutional investors and hedge funds own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.